Financial Ratios

ALEMBIC PHARMACEUTICALS LTD.

NSE : APLLTDBSE : 533573ISIN CODE : INE901L01018Industry : Pharmaceuticals & DrugsHouse : Alembic
BSE942.3512.35 (+1.33 %)
PREV CLOSE ( ) 930.00
OPEN PRICE ( ) 933.55
BID PRICE (QTY) 939.60 (1)
OFFER PRICE (QTY) 941.10 (1)
VOLUME 2974
TODAY'S LOW / HIGH ( )915.25 948.95
52 WK LOW / HIGH ( )527.35 1093.05
NSE942.1011.05 (+1.19 %)
PREV CLOSE( ) 931.05
OPEN PRICE ( ) 929.95
BID PRICE (QTY) 941.00 (8)
OFFER PRICE (QTY) 942.10 (3)
VOLUME 57457
TODAY'S LOW / HIGH( ) 913.95 948.75
52 WK LOW / HIGH ( )527.35 1094
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)17.6427.6555.7951.4332.42
   CEPS(Rs)31.5342.1565.0858.6238.03
   DPS(Rs)8.0010.0014.0010.005.50
   Book NAV/Share(Rs)224.59269.16259.57177.51143.89
   Tax Rate(%)-0.2317.3918.0316.9220.06
Margin Ratios
   Core EBITDA Margin(%)12.9018.0528.6028.8423.48
   EBIT Margin(%)7.6713.4126.6628.8421.30
   Pre Tax Margin(%)6.7213.0726.4028.2320.89
   PAT Margin (%)6.7310.7921.6423.4616.70
   Cash Profit Margin (%)12.0316.4525.2426.7419.58
Performance Ratios
   ROA(%)5.247.7316.9217.9814.39
   ROE(%)7.1510.4625.9632.0024.91
   ROCE(%)7.2011.7225.4027.0823.66
   Asset Turnover(x)0.780.720.780.770.86
   Sales/Fixed Asset(x)1.621.942.412.602.83
   Working Capital/Sales(x)4.194.323.745.926.15
Efficiency Ratios
   Fixed Capital/Sales(x)0.620.510.420.380.35
   Receivable days77.6151.1143.4458.4657.91
   Inventory Days94.7099.2686.9986.7677.85
   Payable days128.19133.30128.78151.10196.12
Valuation Parameters
   PER(x)28.1126.8117.3010.3816.36
   PCE(x)15.7317.5914.839.1013.95
   Price/Book(x)2.212.753.723.013.69
   Yield(%)1.611.351.451.871.04
   EV/Net Sales(x)2.013.013.832.832.98
   EV/Core EBITDA(x)15.5015.8112.668.7512.33
   EV/EBIT(x)26.2222.4914.379.8214.00
   EV/CE(x)1.712.112.821.932.32
   M Cap / Sales1.892.893.742.432.73
Growth Ratio
   Net Sales Growth(%)2.26-0.6222.6112.9024.28
   Core EBITDA Growth(%)-30.42-37.3914.6251.1338.47
   EBIT Growth(%)-41.49-50.0313.3252.9245.04
   PAT Growth(%)-36.21-50.4313.1258.6044.84
   EPS Growth(%)-36.21-50.438.4858.6044.84
Financial Stability Ratios
   Total Debt/Equity(x)0.140.120.100.500.39
   Current Ratio(x)1.791.691.981.421.43
   Quick Ratio(x)0.970.861.010.770.79
   Interest Cover(x)8.0639.66104.0647.3252.42
   Total Debt/Mcap(x)0.070.040.030.170.11

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.